Passage Bio reports FY2024 net loss $64.8M, cash $76.8M; PBFT02 shows durable PGRN elevation in FTD-GRN

Passage BIO, Inc.

Cash, cash equivalents and marketable securities $76.8M as of Dec 31, 2024, down from $114.3M; runway extended into 1Q 2027.
Net loss of $12.7M ($0.20 per share) for Q4 2024 vs $16.8M ($0.30) a year ago; full year net loss $64.8M ($1.07) vs $102.1M.
Dose 1 PBFT02 increased CSF PGRN from <3 ng/mL to 13-27 ng/mL at 6 months (n=4) and 22-34 ng/mL at 12 months (n=2).
Plasma NfL levels 13% lower vs baseline at 12 months vs expected 29% annual increase from natural history data.
First FTD-GRN patient enrolled with Dose 2 (50% lower); plan to report 12-month data and interim Dose 2 data in 2H 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.